Buyout before a FDA decision After GSK's 2B$US move on BELLUS that was 2y before FDA approval, here's another example of a pharmas making a move 3 months before a FDA decision:
Astellas keeps the big buyouts rolling, inking $5.9B Iveric takeover ahead of FDA eye disease ruling
By Nick Paul Taylor May 1, 2023 08:13am
The multibillion-dollar biotech buyouts keep on coming. Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche.
Iveric is less than three months away from learning whether the FDA will approve avacincaptad pegol